Literature DB >> 14597879

Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells.

Alessandra Galetto1, Stefano Buttiglieri, Sarah Forno, Francesco Moro, Antonio Mussa, Lina Matera.   

Abstract

The way a tumor cell dies is believed to influence both its engulfment by dendritic cells (DC) and access of the relevant antigen(s) to the cross-presentation pathway. Here we have studied the effect of lymphokine activated killer (LAK) cells, gamma-radiation and the antimetabolite drug 5-fluorouracil (5-FU) on tumor uptake by HLA-matched DC, and DC presentation of tumor antigens to autologous T lymphocytes. LAK cells and radiation were the best inducers of apoptotic death (Annexin-V+/propidium iodide-) on the gastric cell line KATO III and a primary gastric carcinoma, respectively. The highest rate of tumor uptake by monocyte-derived, granulocyte macrophage colony stimulating factor/interleukin (IL)-4-driven DC was associated with 5-FU, followed by radiation. These treatments also induced high levels of heat shock protein (hsp70). In contrast, only DC that had been taken up 5-FU- or LAK-treated tumors up-modulated IL-12 and presented tumor-associated antigens with increased efficiency, as shown by class I MHC-restricted interferon-gamma release and cytotoxic responses by autologous lymphocytes. Together, these data indicate that apoptotic death induced by anti-cancer therapies can induce distinct patterns of class I MHC cross-presentation of gastric carcinoma-associated antigens to cytotoxic T lymphocyte precursors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597879     DOI: 10.1097/00001813-200311000-00010

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  21 in total

1.  Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Authors:  Lukas W Pfannenstiel; Samuel S K Lam; Leisha A Emens; Elizabeth M Jaffee; Todd D Armstrong
Journal:  Cell Immunol       Date:  2010-03-06       Impact factor: 4.868

2.  Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.

Authors:  Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

Review 3.  From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.

Authors:  Ravi A Madan; Jeanny B Aragon-Ching; James L Gulley; William L Dahut
Journal:  Expert Rev Vaccines       Date:  2011-06       Impact factor: 5.217

Review 4.  Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.

Authors:  Margaret E Gatti-Mays; Jason M Redman; Julie M Collins; Marijo Bilusic
Journal:  Hum Vaccin Immunother       Date:  2017-08-31       Impact factor: 3.452

5.  Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.

Authors:  Terry R Medler; Tiziana Cotechini; Lisa M Coussens
Journal:  Trends Cancer       Date:  2015-09-01

Review 6.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Authors:  L Bracci; G Schiavoni; A Sistigu; F Belardelli
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

7.  In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma.

Authors:  Lina Matera; Alessandra Galetto; Marilena Bello; Cinzia Baiocco; Isabella Chiappino; Giancarlo Castellano; Alessandra Stacchini; Maria A Satolli; Michele Mele; Sergio Sandrucci; Antonio Mussa; Gianni Bisi; Theresa L Whiteside
Journal:  J Transl Med       Date:  2006-11-14       Impact factor: 5.531

Review 8.  Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation.

Authors:  Lotte Spel; Jaap-Jan Boelens; Stefan Nierkens; Marianne Boes
Journal:  Oncoimmunology       Date:  2013-10-21       Impact factor: 8.110

Review 9.  Combinations of immunotherapy and radiation in cancer therapy.

Authors:  Ralph E Vatner; Benjamin T Cooper; Claire Vanpouille-Box; Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2014-11-28       Impact factor: 6.244

10.  iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.

Authors:  Sara De Boo; Joanna Kopecka; Davide Brusa; Elena Gazzano; Lina Matera; Dario Ghigo; Amalia Bosia; Chiara Riganti
Journal:  Mol Cancer       Date:  2009-11-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.